Key facts
- Abrexa Pharmaceuticals’s last known valuation is $75.5M (Apr 2025).
- It has raised $40.1M across 2 recorded rounds; the latest was Early Stage VC ($23.0M) in Apr 2025.
- Notable investors include James Truchard.
- Abrexa Pharmaceuticals has filed 4 Form Ds with the SEC since 2011, most recently Apr 2025 ($23.0M sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Abrexa Pharmaceuticals
Funding rounds
2 roundsAbout Abrexa Pharmaceuticals
Developer of novel drugs designed to treat Alzheimer's disease. The company's research capabilities are focused on developing the oral curcumin derivative J-147, which is reported to address biological aging factors such as preventing the leakage of blood from microvessels in the brain, enabling patients to improve memory, and slowing the degeneration of brain cells.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2011
- Ownership
- Privately Held (backing)
Abrexa Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abrexa Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abrexa Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.